Left ventricular conduit with blood vessel graft

Information

  • Patent Grant
  • 6881199
  • Patent Number
    6,881,199
  • Date Filed
    Tuesday, April 10, 2001
    24 years ago
  • Date Issued
    Tuesday, April 19, 2005
    20 years ago
Abstract
A method of flowing blood from a heart chamber to a coronary vessel includes providing a conduit with a first end and second end, providing the conduit within a heart wall such that the first end of the conduit is open towards the heart chamber and the second end is open towards the blood vessel, and during diastole, restricting a flow of blood from the coronary vessel to the heart chamber via the natural valve.
Description
FIELD OF THE INVENTION

This invention relates to apparatus and method for implanting a conduit to allow communication of fluids from one portion of a patient's body to another; and, more particularly, to a blood flow conduit to allow communication from a heart chamber to a vessel or vice versa, and/or vessel to vessel. Even more particularly, the invention relates to a left ventricular conduit and related conduit configurations having a blood vessel graft incorporated therein for controlling the flow of blood through the conduit to achieve bypass of an occluded or stenosed coronary artery.


BACKGROUND OF THE INVENTION

Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque which, at the very least, can reduce blood and oxygen flow to the heart muscle (myocardium), and may impair the efficiency of the heart's pumping action, and can lead to heart attack (myocardial infarction) and death. In some cases, these coronary arteries can be unblocked through noninvasive techniques such as balloon angioplasty. In more difficult cases, a surgical bypass of the blocked vessel is necessary.


In a coronary bypass operation, one or more venous segments are inserted between the aorta and the coronary artery, or, alternatively, the distal end of an internal mammary artery is anastomosed to the coronary artery at a site distal to the stenosis or occlusion. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.


Such coronary artery bypass graft (CABG) surgery, however, is a very intrusive procedure which is expensive, time-consuming, and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a heart-lung bypass pump so that the heart can be operated on while not beating. A saphenous vein graft is harvested from the patient's leg, another highly invasive procedure, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged. Furthermore, many patients are poor surgical candidates due to other concomitant illnesses.


As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type or location of the blockage or stenosis, or due to the risk of emboli.


Thus, there is a need for an improved coronary bypass system which is less traumatic to the patient.


SUMMARY OF THE INVENTION

The present invention addresses the need in the previous technology by providing a coronary bypass system which avoids a sternotomy and other intrusive aspects associated with coronary bypass surgery. It also frees the surgeon from having to perform multiple anastomoses, as is necessary in the current process.


The present device provides a conduit for diverting blood directly from a heart chamber, such as the left ventricle of the heart, to the coronary artery distal to the blockage or stenosis, thereby bypassing the blocked portion of the vessel. The conduit comprises a tube adapted to be positioned in the heart wall and having a section of blood vessel attached to the interior of the conduit, to provide a passage for blood flow which is similar to the body's own blood vessels.


The conduit device is delivered through the coronary artery to a position distal the blockage or stenosis. At that position, the coronary artery and the wall of the left ventricle, including the myocardium, are pierced to provide an opening or channel completely through from the coronary artery to the left ventricle of the heart. The conduit is then positioned in the opening to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage or stenosis.


The conduit is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. Prior to implantation of the conduit, a section of vein or other blood vessel is obtained from the patient, from another human donor, or from a nonhuman animal. The vein or other blood vessel is sized so as to fit within the interior of the conduit. The hollow lumen of the conduit with the blood vessel graft inserted therein provides a passage for the flow of blood.


If desired, the section of blood vessel inserted into the conduit may include one or more naturally occurring one-way valves. The valve prevents the backflow of blood from the myocardium into the left ventricle. For example, a section of vein having a valve therein can be used. Alternatively, the pulmonic valve or aortic valve obtained from a nonhuman animal, such as a fetal pig or piglet, can be used to provide a one-way passage for the flow of blood through the conduit.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a schematic, cross-sectional view of a human heart, showing a conduit in the myocardium of the heart for forming a bypass between the left ventricle and a coronary artery;



FIG. 1B is an enlarged view of the bypass conduit of FIG. 1A;



FIG. 2 is an exploded view of a vein graft incorporated into a heart conduit in accordance with the preferred arrangement;



FIG. 3 is a close-up, cross-sectional view of a blockage or stenosis in the coronary artery, illustrating the conduit of the preferred arrangement positioned so as to bypass the blockage or stenosis.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. Oxygenated blood that has returned from the lungs to the heart then flows from the heart to the aorta. Some blood in the aorta flows into the coronary arteries, and the remainder of blood in the aorta flows on to the rest of the body. The coronary arteries are the primary blood supply to the heart muscle and are thus critical to life. In some individuals, atherosclerotic plaque, aggregated platelets, and/or thrombi build up within the coronary artery, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death. The presence of coronary vasospasm, also known as “variant angina” or “Prinzmetal's angina,” compounds this problem in many patients.


As used herein, the term “heart chamber” primarily refers to the interior, or lumenal, aspect of the left or right ventricle or the left or right atrium. The term “conduit,” “stent,” and “tube” herein refer to physical structures, preferably primarily artificial, that can be positioned between two or more chambers or vessels, to allow blood flow from one chamber or vessel to another. A “shunt” is any natural or artificial passage between natural channels, such as heart chambers or blood vessels. The conduit in the preferred arrangement can be made of a variety of materials, including various metals, such as nitinol, or plastics.


As used herein, the term “heart wall” comprises any one or more of the following portions or layers of the mammalian heart: the epicardium, myocardium, endocardium, pericardium, interatrial septum, and interventricular septum.


The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.


In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other nonmyocardial and even noncardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.


The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the obstructions that are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.


The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.


The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods are disclosed. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.


In order to restore the flow of oxygenated blood through the coronary artery, the preferred arrangement provides for the shunting of blood directly from the heart to a site in the coronary artery which is distal the blockage or stenosis.


Although the specification herein will describe the conduit primarily with reference to the left ventricle, the preferred arrangement can be used with any of the four heart chambers, and with any coronary artery, including the left main coronary artery, the right coronary artery, the left anterior descending artery, the left circumflex artery, the posterior descending artery, the obtuse marginal branch or a diagonal branch.


A tunnel or opening is formed through the wall of the coronary artery and the myocardium and into the left ventricle of the heart which lies beneath, or deep to, the coronary artery. A conduit is positioned in the opening to keep it open.


The conduit may be introduced into the myocardium in a variety of ways, including by a catheter threaded through the femoral artery into the aorta and thence into the left ventricle and, if necessary, the left atrium; or by a catheter threaded through the femoral vein into the inferior vena cava and thence into the right atrium and right ventricle. Alternatively, the conduit may be introduced through a surgical incision in chest wall (thoracotomy) or sternum (sternotomy).


Further details regarding conduits and conduit delivery systems are described in copending patent applications entitled, DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,048, filed Aug. 4, 1999, VALVE DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/368,393, filed Aug. 4, 1999, LEFT VENTRICULAR CONDUITS TO CORONARY ARTERIES AND METHODS FOR CORONARY BYPASS, U.S. Application Ser. No. 09/534,038, filed Mar. 24, 2000, and BLOOD FLOW CONDUIT DELIVERY SYSTEM AND METHOD OF USE, U.S. application Ser. No. 09/368,644, filed Aug. 4, 1999, and U.S. Pat. Nos. 6,261,304, 5,429,144 and 5,662,124, the disclosures of which are all hereby incorporated by reference in their entirety.


The opening through the heart wall (including endocardium, myocardium, and epicardium) and coronary artery can be formed in a variety of ways, including by knife or scalpel, electrocautery, cryoablation, radiofrequency ablation, ultrasonic ablation, and the like. Other methods will be apparent to those of ordinary skill in the art.


The conduit is provided with a section of vein or other blood vessel positioned within its interior lumen. The section of vein or other blood vessel is obtained from the patient, from a donor, or from an animal. Prior to implantation of the conduit, a segment of blood vessel sized to fit with the lumen of the conduit is inserted into the conduit. The conduit with the graft therein provides a passage for the flow of blood which is similar to the natural human blood vessels. The segment of vein or other blood vessel harvested to fit within the conduit may include one or more of the valves which naturally occur in the human body. These valves act to prevent the backflow of blood. In the conduit, these naturally occurring venous valves prevent the blood from flowing back into the left ventricle of the heart from the coronary artery. The segment of vein is preferably inserted into the conduit prior to the conduit's deployment into the human body by any of various surgical or catheter-guided techniques known to those of skill in the art.


Referring now to FIGS. 1A and 1B, a coronary artery bypass is accomplished by disposing a conduit 12 (FIG. 1B) in a heart wall or myocardium MYO of a patient's heart PH (FIG. 1A). The conduit 12 preferably extends from the left ventricle LV of heart PH to a clogged coronary artery CA at a point downstream of a blockage BL to create a passageway 8 therethrough. Conduit 12 is preferably made of a biocompatible material such as stainless steel or nitinol, although other materials such as Ti, Ti alloys, Ni alloys, Co alloys and biocompatible polymers may also be used. In one embodiment, conduit 12 has a one way valve 6 to allow blood to flow from the left ventricle LV to the coronary artery CA. Although the conduit 12 may elastically deform under the contractive pressure of the heart muscle during systole, the stent remains open to allow blood to pass from the patient's left ventricle LV into the coronary artery CA. During diastole, the blood pumped into coronary artery through passageway 8 is blocked by one-way valve 6 from returning to left ventricle LV.


As shown in FIG. 2, a preferred embodiment involves the use of a vein graft 10 taken from the patient. Prior to preparing the conduit 12 for placement in the patient, a section of vein 10 is obtained from the patient (i.e., an autologous graft or autograft). Of course, a blood vessel taken from another human donor (i.e., an allogeneic graft or allograft) or nonhuman animal species (i.e., a heterologous graft or xenograft) could also be used. The vein 10 is preferably taken from the saphenous vein in the leg of the patient. Alternatively, a donor vein could be used, or a fetal pig or piglet can be obtained and dissected to remove a section of the pulmonary artery having a pulmonic valve therein, or a section of the aorta having an aortic valve therein, or a similar vessel having a naturally occurring valve system. In other embodiments, the endothelial lining of a vein and/or a valve may be grown from one or more tissue cultures, utilizing cloning of donor cell lines or other genetic engineering techniques (or “tissue engineering”) known to those of skill in the art. Thus, as used herein, “a section of blood vessel” may include one or more of the following: a surgically resected segment of a blood vessel, with or without one or more valves; the endothelial lining of a blood vessel, taken from an in vitro or in vivo specimen; and one or more venous valves, taken from in vitro or in vivo specimens.


As noted above, the section of vein 10 or other blood vessel harvested preferably contains one or more valves 14, which occur naturally in the veins. The section of vein 10 may also not have a valve. The vein section 10 is sized so as to be the same length as the conduit 12. The vein section 10 is placed within the interior lumen of the conduit 12 and attached to the inside of the conduit 12 by suturing or other attachment methods. The natural vein graft 10 is biocompatible and therefore reduces problems associated with rejection of the conduit 12 and clotting around or in the conduit 12. In addition, the vein 10 provides a natural valve system 14 that is already used throughout the human body to prevent the backflow of blood. In the case of a xenograft, treatment of the graft with chemicals, such as glutaraldehyde, may be undertaken to remove living cells, including antigenic materials, from the connective tissue framework of the graft so as to reduce thrombogenicity and antigenicity.


Referring now to FIG. 3, a self-expanding conduit 12 having a section of vein 10 therein is introduced into the wall of the myocardium MYO as follows. A conduit delivery catheter (not shown), having the compressed conduit 12 mounted on its distal end, is advanced over a puncture mechanism and into the wall of the myocardium MYO at a site distal to the blockage or stenosis BL in the coronary artery CA. When the conduit 12 is properly seated in the myocardial wall MYO, its retaining sheath is withdrawn, allowing the conduit 12 to expand and open a passageway, or maintain patency of the passageway, from the left ventricle of the heart LV to the coronary artery CA. This allows oxygenated blood to flow directly from the left ventricle of the heart LV through the conduit 12 and to the coronary artery CA, bypassing the section of coronary artery CA that is blocked BL, as shown by the arrows in FIG. 3.


The conduit 12 may include attachment mechanisms not limited to hooks, barbs, large collars, and/or other methods to ensure that a seal is created between the coronary artery CA and the wall of the heart wall MYO, to prevent hemorrhaging and to prevent the threat of or actual conduit migration. When positioning and securing of the conduit 12 is completed, the remaining catheter assembly is removed, leaving the conduit 12 with the vein graft therein, in place in the body


The present vascular conduit having a blood vessel graft incorporated therein provides significant improvements in the present treatment of blockages or stenoses in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way by the foregoing.

Claims
  • 1. A method of flowing blood from a heart chamber to a coronary vessel, the method comprising: providing a conduit with a first end and a second end; providing a natural valve; placing the conduit within a heart wall such that the first end of the conduit is open towards the heart chamber and the second end is open towards the blood vessel; and during diastole, restricting a flow of blood from the coronary vessel to the heart chamber via the natural valve.
  • 2. The method of claim 1, wherein providing the natural valve includes providing a section of blood vessel containing at least one naturally occurring valve.
  • 3. The method of claim 2, wherein the section of blood vessel is a human vein.
  • 4. The method of claim 2, wherein the section of blood vessel is an autograft.
  • 5. The method of claim 2, wherein the section of blood vessel is an allograft.
  • 6. The method of claim 2, wherein the section of blood vessel is a xenograft.
  • 7. The method of claim 1, wherein providing the natural valve includes providing the natural valve inside the conduit.
  • 8. The method of claim 1, wherein the heart chamber is a left ventricle.
  • 9. The method of claim 1, wherein the coronary vessel is a coronary artery.
  • 10. A bypass system for implantation in a body of a patient, the system comprising: a tube having a first end and a second end and being configured to be implanted in a heart wall such that the first end is open towards a heart chamber and the second end is open towards a coronary vessel, the tube being further configured to permit blood to flow therethrough from the heart chamber to the coronary vessel; and a natural valve configured to restrict blood flow from the coronary vessel to the heart chamber during diastole.
  • 11. The system of claim 10, wherein the natural valve includes a section of blood vessel containing at least one naturally occurring valve.
  • 12. The system of claim 11, wherein the section of blood vessel lines an interior of the tube.
  • 13. The system of claim 11, wherein the section of blood vessel is a human vein.
  • 14. The system of claim 11, wherein the section of blood vessel is an autograft.
  • 15. The system of claim 11, wherein the section of blood vessel is an allograft.
  • 16. The system of claim 11, wherein the section of blood vessel is a xenograft.
  • 17. The system of claim 10, wherein the natural valve is disposed inside the tube.
  • 18. The system of claim 10, wherein the heart chamber is a left ventricle.
  • 19. The system of claim 10, wherein the coronary vessel is a coronary artery.
CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation of U.S. application Ser. No. 09/369,061, filed Aug. 4, 1999 now U.S. Pat. No. 6,254,564, which claims the benefits of U.S. Provisional Application No. 60/099,719, filed Sep. 10, 1998, all of which are incorporated herein by reference.

US Referenced Citations (286)
Number Name Date Kind
4118806 Porier et al. Oct 1978 A
4441215 Kaster Apr 1984 A
4546499 Possis et al. Oct 1985 A
4562597 Possis et al. Jan 1986 A
4733665 Palmaz Mar 1988 A
4769029 Patel Sep 1988 A
4953553 Tremulis Sep 1990 A
5147388 Yamazaki Sep 1992 A
5193546 Shaknovich Mar 1993 A
5258008 Wilk Nov 1993 A
5275580 Yamazaki Jan 1994 A
5287861 Wilk Feb 1994 A
5330486 Wilk Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5344426 Lau et al. Sep 1994 A
5389096 Aita et al. Feb 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5429144 Wilk Jul 1995 A
5456712 Maginot Oct 1995 A
5470320 Tifenbrun et al. Nov 1995 A
5500014 Quijano et al. Mar 1996 A
5527337 Stack et al. Jun 1996 A
5545214 Stevens Aug 1996 A
5554119 Harrison et al. Sep 1996 A
5571167 Maginot Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5593434 Williams Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5618299 Khosravi et al. Apr 1997 A
5655548 Nelson et al. Aug 1997 A
5662124 Wilk Sep 1997 A
5733267 Del Toro Mar 1998 A
5755682 Knudson May 1998 A
5758663 Wilk et al. Jun 1998 A
5797946 Chin Aug 1998 A
5807384 Mueller Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5824038 Wall Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5830222 Makower Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5865723 Love Feb 1999 A
5876373 Giba et al. Mar 1999 A
5878751 Hussein et al. Mar 1999 A
5885259 Berg Mar 1999 A
5908028 Wilk Jun 1999 A
5908029 Knudson et al. Jun 1999 A
5922022 Nash et al. Jul 1999 A
5925012 Murphy-Chutorian et al. Jul 1999 A
5931848 Saadat Aug 1999 A
5935119 Guy et al. Aug 1999 A
5935161 Robinson et al. Aug 1999 A
5938632 Ellis Aug 1999 A
5944019 Knudson et al. Aug 1999 A
5971993 Hussein et al. Oct 1999 A
5976155 Foreman et al. Nov 1999 A
5976178 Goldstein et al. Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5976650 Campbell et al. Nov 1999 A
5979455 Maginot Nov 1999 A
5980533 Holman Nov 1999 A
5980548 Evans et al. Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5989276 Houser et al. Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993481 Marcade et al. Nov 1999 A
5997525 March et al. Dec 1999 A
5997563 Kretzers Dec 1999 A
5997573 Quijano et al. Dec 1999 A
5999678 Murphy-Chutorian et al. Dec 1999 A
6001123 Lau Dec 1999 A
6004261 Sinofsky et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007543 Ellis et al. Dec 1999 A
6010449 Selmon et al. Jan 2000 A
6026814 LaFontaine et al. Feb 2000 A
6029672 Vanney et al. Feb 2000 A
6033582 Lee et al. Mar 2000 A
6035856 LaFontaine et al. Mar 2000 A
6036677 Javier, Jr. et al. Mar 2000 A
6036697 DiCaprio Mar 2000 A
6042581 Ryan et al. Mar 2000 A
6045565 Ellis et al. Apr 2000 A
6053924 Hussein Apr 2000 A
6053942 Eno et al. Apr 2000 A
6056743 Ellis et al. May 2000 A
6067988 Mueller May 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6076529 Vanney et al. Jun 2000 A
6080163 Hussein et al. Jun 2000 A
6080170 Nash et al. Jun 2000 A
6092526 LaFontaine et al. Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6093177 Javier, Jr. et al. Jul 2000 A
6093185 Ellis et al. Jul 2000 A
6102941 Tweden et al. Aug 2000 A
6113630 Vanney et al. Sep 2000 A
6113823 Eno Sep 2000 A
6120520 Saadat et al. Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6126649 VanTassel et al. Oct 2000 A
6126654 Giba et al. Oct 2000 A
6126686 Badylak et al. Oct 2000 A
6132451 Payne et al. Oct 2000 A
6139541 Vanney et al. Oct 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6157852 Selmon et al. Dec 2000 A
6159225 Makower Dec 2000 A
6162245 Jayaraman Dec 2000 A
6165185 Shennib et al. Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171251 Mueller et al. Jan 2001 B1
6182668 Tweden et al. Feb 2001 B1
6186972 Nelson et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6193726 Vanney Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6197050 Eno et al. Mar 2001 B1
6197296 Davies et al. Mar 2001 B1
6197324 Crittenden Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6203556 Evans et al. Mar 2001 B1
6213126 LaFontaine et al. Apr 2001 B1
6214041 Tweden et al. Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6217549 Selmon et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6221049 Selmon et al. Apr 2001 B1
6223752 Vanney et al. May 2001 B1
6224584 March et al. May 2001 B1
6231546 Milo et al. May 2001 B1
6231551 Barbut May 2001 B1
6231587 Makower May 2001 B1
6235000 Milo et al. May 2001 B1
6237607 Vanney et al. May 2001 B1
6238406 Ellis et al. May 2001 B1
6241667 Vetter et al. Jun 2001 B1
6241741 Duhaylongsod et al. Jun 2001 B1
6248112 Gambale et al. Jun 2001 B1
6250305 Tweden Jun 2001 B1
6251079 Gambale et al. Jun 2001 B1
6251116 Shennib et al. Jun 2001 B1
6251418 Ahern et al. Jun 2001 B1
6253768 Wilk Jul 2001 B1
6253769 LaFontaine et al. Jul 2001 B1
6254564 Wilk et al. Jul 2001 B1
6258052 Milo Jul 2001 B1
6258119 Hussein et al. Jul 2001 B1
6261304 Hall et al. Jul 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6285903 Rosenthal et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6290709 Ellis et al. Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6322548 Payne et al. Nov 2001 B1
6330884 Kim Dec 2001 B1
6350248 Knudson et al. Feb 2002 B1
6361519 Knudson et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B1
6363939 Wilk Apr 2002 B1
6375615 Flaherty et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6387119 Wolf et al. May 2002 B1
6390098 LaFontaine et al. May 2002 B1
6395208 Herweck et al. May 2002 B1
6402740 Ellis et al. Jun 2002 B1
6406488 Tweden et al. Jun 2002 B1
6406491 Vanney Jun 2002 B1
6409697 Eno et al. Jun 2002 B1
6409751 Hall et al. Jun 2002 B1
6416490 Ellis et al. Jul 2002 B1
6423089 Gingras et al. Jul 2002 B1
6432119 Saadat Aug 2002 B1
6432126 Gambale et al. Aug 2002 B1
6432127 Kim et al. Aug 2002 B1
6432132 Cottone et al. Aug 2002 B1
6443158 LaFontaine et al. Sep 2002 B1
6447522 Gambale et al. Sep 2002 B1
6447539 Nelson et al. Sep 2002 B1
6454760 Vanney Sep 2002 B1
6454794 Knudson et al. Sep 2002 B1
6458092 Gambale et al. Oct 2002 B1
6458140 Akin et al. Oct 2002 B1
6458323 Boekstegers Oct 2002 B1
6464709 Shennib et al. Oct 2002 B1
6475226 Belef et al. Nov 2002 B1
6475244 Herweck et al. Nov 2002 B1
6482220 Mueller Nov 2002 B1
6491689 Ellis et al. Dec 2002 B1
6491707 Makower et al. Dec 2002 B1
6508825 Selmon et al. Jan 2003 B1
6511458 Milo et al. Jan 2003 B1
6514217 Selmon et al. Feb 2003 B1
6514271 Evans et al. Feb 2003 B1
6517558 Gittings et al. Feb 2003 B1
6524323 Nash et al. Feb 2003 B1
6544230 Flaherty et al. Apr 2003 B1
6559132 Holmer May 2003 B1
6561998 Roth et al. May 2003 B1
6565528 Mueller May 2003 B1
6565594 Herweck et al. May 2003 B1
6569145 Shmulewitz et al. May 2003 B1
6569147 Evans et al. May 2003 B1
6610100 Phelps et al. Aug 2003 B1
6641610 Wolf et al. Nov 2003 B1
6651670 Rapacki et al. Nov 2003 B1
6666863 Wentzel et al. Dec 2003 B1
6669709 Cohn et al. Dec 2003 B1
6685648 Flaherty et al. Feb 2004 B1
6694983 Wolf et al. Feb 2004 B1
20010000041 Selmon et al. Mar 2001 A1
20010004683 Gambale et al. Jun 2001 A1
20010004690 Gambale et al. Jun 2001 A1
20010004699 Gittings et al. Jun 2001 A1
20010008969 Evans et al. Jul 2001 A1
20010012948 Vanney Aug 2001 A1
20010014813 Saadat et al. Aug 2001 A1
20010016700 Eno et al. Aug 2001 A1
20010018596 Selmon et al. Aug 2001 A1
20010020172 Selmon et al. Sep 2001 A1
20010025643 Foley Oct 2001 A1
20010027287 Shmulewitz et al. Oct 2001 A1
20010029385 Shennib et al. Oct 2001 A1
20010034547 Hall et al. Oct 2001 A1
20010037117 Gambale et al. Nov 2001 A1
20010037149 Wilk Nov 2001 A1
20010039426 Makower et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010041902 Lepulu et al. Nov 2001 A1
20010044631 Akin et al. Nov 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010049523 DeVore et al. Dec 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020002349 Flaherty et al. Jan 2002 A1
20020004662 Wilk Jan 2002 A1
20020004663 Gittings et al. Jan 2002 A1
20020007138 Wilk et al. Jan 2002 A1
20020029079 Kim et al. Mar 2002 A1
20020032476 Gambale et al. Mar 2002 A1
20020049486 Knudson et al. Apr 2002 A1
20020058897 Renati Apr 2002 A1
20020062146 Makower et al. May 2002 A1
20020065478 Knudson et al. May 2002 A1
20020072699 Knudson et al. Jun 2002 A1
20020077566 Laroya et al. Jun 2002 A1
20020077654 Javier, Jr. et al. Jun 2002 A1
20020092535 Wilk Jul 2002 A1
20020092536 LaFontaine et al. Jul 2002 A1
20020095111 Tweden et al. Jul 2002 A1
20020100484 Hall et al. Aug 2002 A1
20020111627 Kim et al. Aug 2002 A1
20020123698 Garibotto et al. Sep 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20020138087 Shennib et al. Sep 2002 A1
20020143285 Eno et al. Oct 2002 A1
20020143289 Ellis et al. Oct 2002 A1
20020144696 Sharkaway et al. Oct 2002 A1
20020161383 Akin et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020165479 Wilk Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
20020179098 Makower et al. Dec 2002 A1
20020183716 Herweck et al. Dec 2002 A1
20020193782 Ellis et al. Dec 2002 A1
20030018379 Knudson et al. Jan 2003 A1
20030044315 Boekstegers Mar 2003 A1
20030045828 Wilk Mar 2003 A1
20030055371 Wolf et al. Mar 2003 A1
20030073973 Evans et al. Apr 2003 A1
20030078561 Gambale et al. Apr 2003 A1
20030100920 Akin et al. May 2003 A1
20030105514 Phelps et al. Jun 2003 A1
20030120195 Milo et al. Jun 2003 A1
20030181938 Roth et al. Sep 2003 A1
20030195458 Phelps et al. Oct 2003 A1
20030216679 Wolf et al. Nov 2003 A1
20030236542 Makower Dec 2003 A1
20040015225 Kim et al. Jan 2004 A1
20040019348 Stevens et al. Jan 2004 A1
Foreign Referenced Citations (143)
Number Date Country
0 732 088 Sep 1996 EP
0 815 798 Jul 1997 EP
0 829 239 Aug 1997 EP
0 792 624 Sep 1997 EP
0 797 957 Oct 1997 EP
0 797 958 Oct 1997 EP
0 799 604 Oct 1997 EP
0 801 928 Oct 1997 EP
0 836 834 Oct 1997 EP
0 876 796 May 1998 EP
0 853 921 Jul 1998 EP
0 858 779 Aug 1998 EP
0 876 803 Nov 1998 EP
0 888 750 Jan 1999 EP
0 895 752 Feb 1999 EP
1 020 166 Jul 2000 EP
1 027 870 Aug 2000 EP
1 097 676 May 2001 EP
1 166 721 Jan 2002 EP
0 959 815 Dec 2002 EP
2 316 322 Feb 1998 GB
WO 9632972 Oct 1996 WO
WO 9635469 Nov 1996 WO
WO 9639962 Dec 1996 WO
WO 9639964 Dec 1996 WO
WO 9639965 Dec 1996 WO
9713463 Apr 1997 WO
9713471 Apr 1997 WO
9727893 Aug 1997 WO
9727897 Aug 1997 WO
WO 9727898 Aug 1997 WO
9732551 Sep 1997 WO
WO 9743961 Nov 1997 WO
WO 9803118 Jan 1998 WO
9806356 Feb 1998 WO
9808456 Mar 1998 WO
9810714 Mar 1998 WO
9816161 Apr 1998 WO
WO 9824373 Jun 1998 WO
WO 9825533 Jun 1998 WO
WO 9838916 Sep 1998 WO
WO 9838925 Sep 1998 WO
WO 9838939 Sep 1998 WO
WO 9838941 Sep 1998 WO
WO 9839038 Sep 1998 WO
9844869 Oct 1998 WO
9846115 Oct 1998 WO
9846119 Oct 1998 WO
9849964 Nov 1998 WO
9853759 Dec 1998 WO
9855027 Dec 1998 WO
WO 9857590 Dec 1998 WO
9857591 Dec 1998 WO
WO 9857592 Dec 1998 WO
WO 9907296 Feb 1999 WO
9908624 Feb 1999 WO
9949793 Mar 1999 WO
WO 9915220 Apr 1999 WO
WO 9917671 Apr 1999 WO
9917683 Apr 1999 WO
9921490 May 1999 WO
9921510 May 1999 WO
WO 9922655 May 1999 WO
9922656 May 1999 WO
WO 9922658 May 1999 WO
9925273 May 1999 WO
WO 9927985 Jun 1999 WO
WO 9935977 Jul 1999 WO
WO 9935979 Jul 1999 WO
WO 9935980 Jul 1999 WO
9936000 Jul 1999 WO
9936001 Jul 1999 WO
9938459 Aug 1999 WO
WO 9940853 Aug 1999 WO
9940868 Aug 1999 WO
WO 9940963 Aug 1999 WO
WO 9944524 Sep 1999 WO
9947071 Sep 1999 WO
9948545 Sep 1999 WO
WO 9948549 Sep 1999 WO
9949910 Oct 1999 WO
9951162 Oct 1999 WO
9953863 Oct 1999 WO
WO 9955406 Nov 1999 WO
9960941 Dec 1999 WO
9962430 Dec 1999 WO
0009195 Feb 2000 WO
WO 0015275 Feb 2000 WO
0010623 Mar 2000 WO
0012029 Mar 2000 WO
WO 0013722 Mar 2000 WO
0015146 Mar 2000 WO
0015147 Mar 2000 WO
WO 0015148 Mar 2000 WO
0015148 Mar 2000 WO
0015149 Mar 2000 WO
0015275 Mar 2000 WO
WO 0018302 Apr 2000 WO
WO 0018323 Apr 2000 WO
WO 0018325 Apr 2000 WO
WO 0018326 Apr 2000 WO
WO 0018331 Apr 2000 WO
WO 0018462 Apr 2000 WO
0021436 Apr 2000 WO
0021461 Apr 2000 WO
0021463 Apr 2000 WO
0024449 May 2000 WO
0028924 May 2000 WO
0033725 Jun 2000 WO
WO 0035376 Jun 2000 WO
WO 0036997 Jun 2000 WO
0041632 Jul 2000 WO
0041633 Jul 2000 WO
WO 0043051 Jul 2000 WO
0045711 Aug 2000 WO
WO 0045886 Aug 2000 WO
0047139 Aug 2000 WO
WO 0049952 Aug 2000 WO
WO 0049954 Aug 2000 WO
WO 0049956 Aug 2000 WO
WO 0054660 Sep 2000 WO
WO 0054661 Sep 2000 WO
WO 0056224 Sep 2000 WO
WO 0056225 Sep 2000 WO
0056387 Sep 2000 WO
0060995 Oct 2000 WO
0066007 Nov 2000 WO
0066009 Nov 2000 WO
0066035 Nov 2000 WO
WO 0069345 Nov 2000 WO
WO 0069504 Nov 2000 WO
0071195 Nov 2000 WO
WO 0108566 Feb 2001 WO
WO 0108602 Feb 2001 WO
WO 0110340 Feb 2001 WO
WO 0110341 Feb 2001 WO
WO 0110347 Feb 2001 WO
WO 0110348 Feb 2001 WO
WO 0110349 Feb 2001 WO
WO 0110350 Feb 2001 WO
0117440 Mar 2001 WO
1 097 676 May 2001 WO
0149187 Jul 2001 WO
Related Publications (1)
Number Date Country
20020007138 A1 Jan 2002 US
Provisional Applications (1)
Number Date Country
60099719 Sep 1998 US
Continuations (1)
Number Date Country
Parent 09369061 Aug 1999 US
Child 09828794 US